BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 15127320)

  • 1. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
    Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM; Barrow BA; Grant PJ; Levy JC
    Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
    Morimitsu LK; Fusaro AS; Sanchez VH; Hagemann CC; Bertini AM; Dib SA
    Diabetes Res Clin Pract; 2007 Dec; 78(3):340-8. PubMed ID: 17544539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
    Sartori MT; Rigotti P; Marchini F; Spiezia L; Baldan N; Furian L; Varvarikis C; Girolami A
    Transplantation; 2003 Apr; 75(7):994-8. PubMed ID: 12698086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
    Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
    Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
    Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
    Henkel E; Gallo S; Siegert G; Koehler C; Hanefeld M
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):327-34. PubMed ID: 17473573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.